Pan-Malaria Transmission-Blocking Vaccine AnAPN1

• Status: Not yet recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Malaria is still responsible for more than 627,000 deaths each year, predominantly among children under 5 years old. Current reductions in deaths have stagnated, and we expect additional setbacks for malaria control programs due to the COVID-19 pandemic. To achieve malaria elimination and eradication we must leverage concerted approaches to reduce clinical disease and prevent new infections. The existing malaria controls tools including the RTS,S (trade name Mosquirix), a malaria vaccine currently undergoing implementation studies and endorsed by the World Health Organization on October 7, 2021, can reduce disease burden for patients but cannot ultimately support malaria elimination and eradication since their effect on malaria transmission is at most partial. Consequently, complementary interventions, such as transmission-blocking vaccines (TBVs) may prove to be a cost-effective intervention that can reduce on-going residual transmission and the cascade of new infections.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Centre de Recherche Médicale de Lambaréné
• Collaborator: Global Health Innovative Technology Fund

Criteria

Inclusion Criteria :

• Healthy male and female volunteers aged 18-45 years.

• Able and willing (in the investigator's opinion) to comply with all trial requirements.

• General good health based on medical history and clinical examination.

• Written informed consent.

• Available to participate in follow up for the duration of trial (6 months following the last injection).

• Reachable by phone during the whole trial period.

• Women only: Must agree to practice continuous effective contraception for the duration of the trial.

Exclusion Criteria:

• Positive for P. falciparum sexual and asexual stages by thick blood smear microscopy on admission and documented parasitologically confirmed malaria parasites of at least 1000 parasite/microliter in the past four weeks.

• Pregnancy, lactation, or intention to become pregnant during the trial.

• Previous participation in a malaria vaccine trial.

• HIV and microscopically detectable schistosomiasis and Soil-Transmitted helminth infection.